http://www.sunherald.com/2011/06/10/3184498/biota-obtains-us29m-n...

http://www.sunherald.com/2011/06/10/3184498/biota-obtains-us29m-nih-grant.html#ixzz1Ov8qJCuB


Management need to sell the full story and update the company profile "About Biota" to include the Inavir BARDA grant and progression to ROW


"Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza?. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product, lnavir?, is approved for marketing in Japan.

Relenza? is a registered trademark of the GlaxoSmithKline group of companies.

Inavir? is registered to Daiichi Sankyo."



Read more: http://www.sunherald.com/2011/06/10/3184498/biota-obtains-us29m-nih-grant.html#ixzz1Ov8qJCuB